HGH Fragment 176-191 vs C-peptide
Head-to-head comparison of HGH Fragment 176-191 (Human Growth Hormone Fragment 176-191) and C-peptide (Connecting peptide (C-peptide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HGH Fragment 176-191 | C-peptide |
|---|---|---|
| Category | Weight Management | Pain Management |
| Full Name | Human Growth Hormone Fragment 176-191 | Connecting peptide (C-peptide) |
| Molecular Weight | 1817.12 g/mol | 3020.3 Da |
| Half-Life | ~30 minutes | ~20-30 min |
| Amino Acids | 16 | 31 |
| Typical Dose | — | no approved analgesic dose|research-only |
| Route | — | IV|subQ |
| Purity | >98% | ≥98% |
| Studies Count | 45 | 46 |
| Research Status | Active Research | Pre-clinical |
HGH Fragment 176-191 Benefits
- ✓Targeted fat loss, no blood sugar impact, no IGF-1 elevation, inhibits lipogenesis, stimulates lipolysis, improved body composition
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
HGH Fragment 176-191 Dosing
250-500 mcg subcutaneously 1-2 times daily on empty stomach. 12-16 week cycles typical in research.
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
HGH Fragment 176-191 Side Effects
- ⚠Injection site irritation, headache, drowsiness. Does not affect blood sugar, insulin sensitivity, or elevate IGF-1.
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Research Overview
HGH Fragment 176-191
This 16-amino-acid fragment specifically targets adipose tissue via beta-3 adrenergic receptors. Works through a GH-receptor-independent pathway, explaining selective fat-loss properties without growth-promoting effects.
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.